Insulin Efsitora Alfa vs insulin icodec

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

Insulin Efsitora Alfa · Onswik

Marketed by Eli Lilly

Approved in Type 2 Diabetesprotein (Fc-fusion)
Partial signal

NCT05275400 · Phase 3 · completed

The study randomized 986 participants to efsitora or active-control insulin degludec, but treatment was open-label rather than blinded. The primary HbA1c noninferiority endpoint was met, with a treatment difference of -0.089 percentage points and a 95% confidence interval of -0.191 to 0.013 within the prespecified 0.4% margin; the primary endpoint was a surrogate measure.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545) (met)

Result source: NCT05662332

insulin icodec · Awiqli

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Partial signal

NCT04760626 · Phase 3 · completed

The study was randomized and actively controlled, but it was open-label, with 542 participants assigned to insulin icodec and 543 to once-daily basal insulin analogues. The primary HbA1c endpoint was met for non-inferiority, but HbA1c is a surrogate measure rather than a hard clinical or endoscopic endpoint, supporting a moderate evidence grade.

Next expected readout: October 2027 · NCT07747402 (registry estimate)

Reported efficacy

Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89) (met)

Result source: NCT06340854

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin Efsitora Alfainsulin icodec
HbA1c, change-1.3% vs -1.2%vs Insulin Degludecwk 52 · n 463NCT05362058
11 other results
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · primary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · primary NCT05275400
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.3% vs -1.2% wk 52 · n 463 · Phase 3 · secondary NCT05362058
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · secondary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · secondary NCT05275400
  • -1.4% vs -1.3% wk 26 · n 463 · Phase 3 · secondary NCT05362058
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -0.6% vs -0.7% wk 32 · n 130 · Phase 2 · primary NCT03736785
  • -0.6% vs -0.7% wk 32 · n 125 · Phase 2 · primary NCT03736785
  • -1.2% vs -1.3% wk 26 · n 127 · Phase 2 · primary NCT04450394
-1.7% vs -1.3%vs Once Daily Basal Insulin Analoguewk 52 · n 542NCT04760626
11 other results
  • -1.6% vs -1.4% wk 52 · n 492 · Phase 3 · primary NCT04460885
  • -0.8% vs -0.6% wk 26 · n 204 · Phase 3 · primary NCT06340854
  • -1.6% vs -1.4% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -0.9% vs -0.7% wk 26 · n 263 · Phase 3 · primary NCT04770532
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.3% vs -1.1% wk 26 · n 122 · Phase 2 · primary NCT03751657
  • -0.5% vs -0.5% wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.8% vs -0.5% wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • -1% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.2% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.4% vs -1.0% wk 16 · n 52 · Phase 2 · secondary NCT03951805
Body weight, change (kg)3.6 vs 3.5vs Insulin Degludecwk 52 · n 465NCT05362058
6 other results
  • 3.9 vs 3.3 wk 52 · n 357 · Phase 3 · secondary NCT05662332
  • 2.3 vs 2.2 500 U/mL · wk 78 · n 654 · Phase 3 · secondary NCT05275400
  • 3.2 vs 2.7 wk 26 · n 465 · Phase 3 · secondary NCT05362058
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 1 vs 2 wk 32 · n 135 · Phase 2 · secondary NCT03736785
  • 1 vs 2 wk 32 · n 130 · Phase 2 · secondary NCT03736785
2.3 vs 1.8vs Insulin Glarginewk 52 · n 492NCT04460885
10 other results
  • 2.0 vs 0.6 wk 26 · n 204 · Phase 3 · secondary NCT06340854
  • 2.8 vs 2.3 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 1.4 vs -0.3 wk 26 · n 263 · Phase 3 · secondary NCT04770532
  • 2.7 vs 2.2 wk 26 · n 291 · Phase 3 · secondary NCT04880850
  • 1.5 vs 1.6 wk 26 · n 122 · Phase 2 · secondary NCT03751657
  • 1.3 vs 0.1 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • 0.6 vs 0.1 wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • 0.9 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.1 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.3 vs 0.6 wk 16 · n 52 · Phase 2 · secondary NCT03951805
HbA1c below 7%—Not reported—Not posted · NCT05013229
Fasting plasma glucose, change—Not reported-3.4 vs -3.3vs Insulin Glarginewk 52 · n 480NCT04460885
9 other results
  • -3.0 vs -3.0 wk 26 · n 284 · Phase 3 · secondary NCT04795531
  • -1.6 vs -1.6 wk 26 · n 260 · Phase 3 · secondary NCT04770532
  • -1.8 vs -1.6 wk 26 · n 283 · Phase 3 · secondary NCT04880850
  • -3.2 vs -3.0 wk 26 · n 121 · Phase 2 · secondary NCT03751657
  • -0.8 vs -0.6 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.7 vs -0.6 wk 16 · n 52 · Phase 2 · secondary NCT03922750
  • -2.2 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -2.4 vs -2.3 wk 16 · n 50 · Phase 2 · secondary NCT03951805
  • -3.0 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
3-point MACE (% with event)—Not reported—Not posted · NCT05013229

HbA1c, change

Insulin Efsitora Alfa
-1.3% vs -1.2%vs Insulin Degludecwk 52 · n 463NCT05362058
11 other results
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · primary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · primary NCT05275400
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.3% vs -1.2% wk 52 · n 463 · Phase 3 · secondary NCT05362058
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · secondary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · secondary NCT05275400
  • -1.4% vs -1.3% wk 26 · n 463 · Phase 3 · secondary NCT05362058
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -0.6% vs -0.7% wk 32 · n 130 · Phase 2 · primary NCT03736785
  • -0.6% vs -0.7% wk 32 · n 125 · Phase 2 · primary NCT03736785
  • -1.2% vs -1.3% wk 26 · n 127 · Phase 2 · primary NCT04450394
insulin icodec
-1.7% vs -1.3%vs Once Daily Basal Insulin Analoguewk 52 · n 542NCT04760626
11 other results
  • -1.6% vs -1.4% wk 52 · n 492 · Phase 3 · primary NCT04460885
  • -0.8% vs -0.6% wk 26 · n 204 · Phase 3 · primary NCT06340854
  • -1.6% vs -1.4% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -0.9% vs -0.7% wk 26 · n 263 · Phase 3 · primary NCT04770532
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.3% vs -1.1% wk 26 · n 122 · Phase 2 · primary NCT03751657
  • -0.5% vs -0.5% wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.8% vs -0.5% wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • -1% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.2% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.4% vs -1.0% wk 16 · n 52 · Phase 2 · secondary NCT03951805

Body weight, change (kg)

Insulin Efsitora Alfa
3.6 vs 3.5vs Insulin Degludecwk 52 · n 465NCT05362058
6 other results
  • 3.9 vs 3.3 wk 52 · n 357 · Phase 3 · secondary NCT05662332
  • 2.3 vs 2.2 500 U/mL · wk 78 · n 654 · Phase 3 · secondary NCT05275400
  • 3.2 vs 2.7 wk 26 · n 465 · Phase 3 · secondary NCT05362058
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 1 vs 2 wk 32 · n 135 · Phase 2 · secondary NCT03736785
  • 1 vs 2 wk 32 · n 130 · Phase 2 · secondary NCT03736785
insulin icodec
2.3 vs 1.8vs Insulin Glarginewk 52 · n 492NCT04460885
10 other results
  • 2.0 vs 0.6 wk 26 · n 204 · Phase 3 · secondary NCT06340854
  • 2.8 vs 2.3 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 1.4 vs -0.3 wk 26 · n 263 · Phase 3 · secondary NCT04770532
  • 2.7 vs 2.2 wk 26 · n 291 · Phase 3 · secondary NCT04880850
  • 1.5 vs 1.6 wk 26 · n 122 · Phase 2 · secondary NCT03751657
  • 1.3 vs 0.1 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • 0.6 vs 0.1 wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • 0.9 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.1 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.3 vs 0.6 wk 16 · n 52 · Phase 2 · secondary NCT03951805

HbA1c below 7%

Insulin Efsitora Alfa
—Not reported
insulin icodec
—Not posted · NCT05013229

Fasting plasma glucose, change

Insulin Efsitora Alfa
—Not reported
insulin icodec
-3.4 vs -3.3vs Insulin Glarginewk 52 · n 480NCT04460885
9 other results
  • -3.0 vs -3.0 wk 26 · n 284 · Phase 3 · secondary NCT04795531
  • -1.6 vs -1.6 wk 26 · n 260 · Phase 3 · secondary NCT04770532
  • -1.8 vs -1.6 wk 26 · n 283 · Phase 3 · secondary NCT04880850
  • -3.2 vs -3.0 wk 26 · n 121 · Phase 2 · secondary NCT03751657
  • -0.8 vs -0.6 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.7 vs -0.6 wk 16 · n 52 · Phase 2 · secondary NCT03922750
  • -2.2 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -2.4 vs -2.3 wk 16 · n 50 · Phase 2 · secondary NCT03951805
  • -3.0 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805

3-point MACE (% with event)

Insulin Efsitora Alfa
—Not reported
insulin icodec
—Not posted · NCT05013229
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. Insulin Efsitora Alfa: 8 of 8 rows · insulin icodec: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin Efsitora Alfa
Rows use multiple source trials
insulin icodec
Rows use multiple source trials
Time Above Range
absolute value · % of time
29.66 vs 33.05 Insulin Degludec % of time @ 52wka
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
26.86 vs 32.27 Insulin Glargine % of time @ 52wka
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below 54 mg/dL
absolute value · percentage points
0.33% (n=368) vs 0.28% (n=360) Insulin Degludec @ 26wkb,c
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.34% (n=238) vs 0.22% (n=239) Insulin Degludec @ 26wkb,c
NCT04770532 · Phase 3
Time Below Range
absolute value · % of time
0.36 vs 0.22 Insulin Degludec % of time @ 26wk500 U/mLa,d
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1 other source trial
6.84 vs 5.25 Insulin Glargine % of time @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.27 vs 0.21 Insulin Glargine % of time @ 52wka,d
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time in Range
absolute value · percentage points
64.27% (n=387) vs 61.18% (n=381) Insulin Degludec @ 52wka
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
71.94% (n=439) vs 66.9% (n=440) Insulin Glargine @ 52wka
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Dropout rate
9.5%500 U/mLe
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
5.4%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
8.8%Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
4.7%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.8%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
0%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
12.6%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
12.9%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
8.3%f
NCT04760626 · Phase 3
show 14 more results
3.7%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
2%
NCT04795531 · Phase 3
1.1%
NCT04770532 · Phase 3
5.5%
NCT04880850 · Phase 3
36.5%Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
2%
NCT05823948 · Phase 3 · registry result, not featured evidence
1.9%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
2.4%
NCT03751657 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.1%500 U/mLe
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
0.6%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.6%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
0%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
0.7%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
0.8%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
—f
NCT04760626 · Phase 3
show 14 more results
—
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT04795531 · Phase 3
—
NCT04770532 · Phase 3
—
NCT04880850 · Phase 3
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—
NCT05823948 · Phase 3 · registry result, not featured evidence
1.9%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
—
NCT03751657 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Serious AEs
15.7%500 U/mLe
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
8.8%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.5%Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.7%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
7.1%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
5.2%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
6.1%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
8.3%f
NCT04760626 · Phase 3
show 14 more results
13%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.8%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.1%
NCT04795531 · Phase 3
8.4%
NCT04770532 · Phase 3
7.6%
NCT04880850 · Phase 3
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.2%Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.9%
NCT05823948 · Phase 3 · registry result, not featured evidence
3.7%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
1.6%
NCT03751657 · Phase 2 · registry result, not featured evidence
5.9%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
500 U/mLe
covid-19 10.7%
nasopharyngitis 9.2%
dose calculation error 6.4%
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 7 more results
nasopharyngitis 9.2%
covid-19 7.9%
upper respiratory tract infection 7.9%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
influenza 7.3%
covid-19 5.3%
hypertension 5.3%
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
anaemia 4.7%
arthralgia 2.3%
diarrhoea 2.3%
NCT04450394 · Phase 2 · registry result, not featured evidence
abdominal discomfort 7.1%
anaemia 7.1%
chest pain 7.1%
NCT04450394 · Phase 2 · registry result, not featured evidence
diarrhoea 6.7%
upper respiratory tract infection 5.9%
cough 0.7%
NCT03736785 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 10.6%
diarrhoea 6.1%
dizziness 5.3%
NCT03736785 · Phase 2 · registry result, not featured evidence
f
covid-19 7.9%
NCT04760626 · Phase 3
show 13 more results
covid-19 17.7%
back pain 8.1%
diarrhoea 7.9%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 13.6%
diarrhoea 5.3%
diabetic retinopathy 2.9%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
covid-19 8.2%
diabetic retinopathy 5.1%
influenza 5.1%
NCT04795531 · Phase 3
nasopharyngitis 8.4%
diarrhoea 5.3%
headache 5.3%
NCT04770532 · Phase 3
covid-19 8.6%
diarrhoea 5.2%
diabetic retinopathy 4.1%
NCT04880850 · Phase 3
nausea 19.1%
vomiting 8.5%
upper respiratory tract infection 7.4%
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 13.7%
covid-19 9.8%
back pain 7.8%
NCT05823948 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.8%
medical device site haemorrhage 9.3%
headache 5.6%
NCT03922750 · Phase 2 · registry result, not featured evidence
nasopharyngitis 14%
hypertension 6%
influenza 6%
NCT03922750 · Phase 2 · registry result, not featured evidence
headache 11.2%
nasopharyngitis 8%
upper respiratory tract infection 5.6%
NCT03751657 · Phase 2 · registry result, not featured evidence
back pain 9.8%
nasopharyngitis 9.8%
headache 0%
NCT03951805 · Phase 2 · registry result, not featured evidence
nasopharyngitis 13.7%
headache 5.9%
back pain 3.9%
NCT03951805 · Phase 2 · registry result, not featured evidence
headache 9.6%
nasopharyngitis 3.8%
back pain 1.9%
NCT03951805 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation context differs: baseline_threshold differs (bmi<=40, hba1c<=11, hba1c>=7 versus bmi<=45); prior_therapy differs (naive versus experienced).
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 52 weeks versus 26 weeks.
  5. ePopulation comparability has not been reviewed for 4 of these studies.
  6. fPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin Efsitora Alfa

Fasting Glucose Change mg/dL -30.97 vs -30.13 Insulin Degludec mg @ 26wk500 U/mL
absolute change · mg
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 4 more results
-46.76 vs -50.92 Glargine mg @ 52wk
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-30.87 vs -26.58 Insulin Glargine mg @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
-13.1 vs -31.5 Insulin Degludec mg @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
-18.6 vs -31.5 Insulin Degludec mg @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
TRIM-D 10.03 vs 6.88 Insulin Degludec score @ 26wk500 U/mL
absolute change · score
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 3 more results
10.09 vs 6.53 Insulin Degludec score @ 52wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.33 vs 6.98 Insulin Degludec score @ 78wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.4 vs 13.87 Glargine score @ 52wk
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
DTSQc - Treatment Satisfaction 14.9 vs 12.3 Insulin Degludec score @ 26wk500 U/mL
absolute value · score
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
15.1 vs 12.3 Insulin Degludec score @ 52wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.4 vs 11.7 Insulin Degludec score @ 78wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
FBG Change mg/dL -57.86 vs -63.04 Insulin Degludec mg @ 26wk
absolute change · mg
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
-59.77 vs -59.97 Insulin Degludec mg @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Glucose Variability CV 26.31% (n=368) vs 26.67% (n=360) Insulin Degludec @ 26wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
26.29% (n=368) vs 26.81% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below 70 mg/dL 1.06% (n=368) vs 0.93% (n=360) Insulin Degludec @ 12wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
1.55% (n=368) vs 1.25% (n=360) Insulin Degludec @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.49% (n=368) vs 1.19% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Event Incidence 25.94% (n=397) vs 29.9% (n=398) Glargine @ 52wk
responder rate · % of participants
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Nocturnal Hypoglycemia Incidence 3.53% (n=397) vs 5.03% (n=398) Glargine @ 52wk
responder rate · % of participants
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
DTSQc - Treatment Satisfaction 15.1 vs 14.5 Glargine score @ 52wk
absolute value · score
Treatment satisfaction score
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
DID-EQ Device Characteristics 91.4 vs 89.6 Glargine score @ 52wk
absolute change · score
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
HbA1c Less Than 7 Without Nocturnal Hypoglycemia 38.6% (n=361) vs 35.9% (n=362) Insulin Glargine @ 26wk
responder rate · % of participants
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
Glucose Variability CV 28.51 vs 28.28 Insulin Glargine Coefficient of Variation @ 26wk
absolute value · Coefficient of Variation
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3

+ 1 further endpoint in the CSV export.

insulin icodec

Fasting Plasma Glucose -3.35 vs -3.33 Insulin Glargine mmol/L @ 52wk
absolute change · mmol/L
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 9 more results
-3.01 vs -2.99 Insulin Degludec mmol/L @ 26wk
NCT04795531 · Phase 3
-1.58 vs -1.62 Insulin Degludec mmol/L @ 26wk
NCT04770532 · Phase 3
-1.75 vs -1.61 Insulin Glargine mmol/L @ 26wk
NCT04880850 · Phase 3
-0.83 vs -0.57 Insulin Glargine U100 mmol/L @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
-0.69 vs -0.57 Insulin Glargine U100 mmol/L @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
-3.2 vs -2.99 Insulin Glargine mmol/L @ 26wk
NCT03751657 · Phase 2 · registry result, not featured evidence
-2.23 vs -2.34 Insulin Glargine mmol/L @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
-2.42 vs -2.34 Insulin Glargine mmol/L @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
-3.01 vs -2.34 Insulin Glargine mmol/L @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
Time Above Range -20.54% (n=202) vs -11.19% (n=198) Insulin Glargine @ 26wk
absolute value · percentage points
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 3 0 vs 2 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
0 vs 0 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
0 vs 1 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
7 vs 3 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
Hypoglycemia Episodes Level 2 53 vs 23 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
50 vs 17 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
113 vs 41 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
937 vs 935 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
Hypoglycemia Episodes Level 2 or 3 53 vs 25 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
50 vs 17 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
113 vs 42 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
944 vs 938 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
DTSQs 4.22 vs 2.96 Insulin Degludec score @ 26wk
absolute change · score
NCT04770532 · Phase 3
Time in Range 66.88 vs 66.44 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3
show 5 more results
65.99 vs 64.98 Insulin Glargine U100 % of time @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
72.86 vs 64.98 Insulin Glargine U100 % of time @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
76.65 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
82.97 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
80.89 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
Time Below 54 mg/dL 0.73 vs 0.61 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3
HbA1c -1.23% (n=91) @ 52wk
absolute change · percentage points
No placebo or comparator arm
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-1.18% (n=50) @ 26wk
NCT05823948 · Phase 3 · registry result, not featured evidence
SMBG 7-point -1.69 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
PPG Excursion -1.27 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
Fasting Plasma Glucose -1.29 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT05813912 · Phase 3 · registry result, not featured evidence · combination

+ 3 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin Efsitora Alfa's landscape · insulin icodec's landscape